scispace - formally typeset
Journal ArticleDOI

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.

Konstantinos Avgoustakis
- 30 Sep 2004 - 
- Vol. 1, Iss: 4, pp 321-333
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.
Abstract
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.

read more

Citations
More filters
Patent

Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells

TL;DR: In this paper, synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
Journal Article

Preparation and characterization of gemcitabine loaded mpeg-pcl polymeric nanoparticles for improved transportation across blood brain barrier

TL;DR: It can be concluded that GCB loaded MPEG-PCL nanoformulation can serve as a potential drug delivery tool for the treatment of brain tumours.
Journal ArticleDOI

Polymer-Based Nanoparticulate Systems as Versatile Agents in the Prognosis and Therapy of Cancer

TL;DR: This review discusses strategies for synthesizing, tailoring and targeting polymeric nanoparticles, schemes for reducing metal nanoparticle toxicity by using polymers, and recent aspects of internalization and biodistribution of nanoparticulate systems with reference to cancer.

Targeted Magnetite Tissue Delivery for Antiretroviral Pharmacokinetics

Tianyuzi Li
TL;DR: TARGETED MAGNETITE TISSUE DELIVERY: IMPLICATIONS TOWARDS IMPROVING ANTI-TROVIRAL PHARMACOKINETICS.

Propolis particles incorporated in aqueous formulations with enhanced antibacterial performance

TL;DR: In this paper, the authors investigated the effect of common carrier phases used for dissolution of propolis for antibacterial assays and formulated the extract into propolis sub-micron aqueous dispersions via direct ultrasonication.
Related Papers (5)